CARDIOVASCULAR BENEFITS- NEWCLINICAL RESEARCH

  • In a study (published in Frontiers in Nutrition February2024), AlmegaPL®
    is clinically shown to decrease riglycerides by 14%, which is 4 times the response expected from other omega-3 sources (Ganuza et al., 2024)
  • Clinically confirmed by two independent studies to decrease remnant cholesterol by up to 25 % (Rao et al., 2020; Ganuza et al., 2024).
  • Neither study showed an increase in LDL cholesterol, which is a unique benefit of EPA-only formulations as studies using fish oil, which naturally contains EPA and DHA, have been shown to increase LDL cholesterol.(Eslick et al., 2009)
  • EPA is emerging as the leading LCn-3 PUFA (long-chain polyunsaturated fatty acid) for supporting optimal key lipid profiles for heart health.
  • AlmegaPL® is the only available natural source of EPA-only, without DHA, unlike other natural forms of omega-s (fish and krill).

    References:

    1. Kagan et al., 2013 Lipids Health Dis.
    2. Rao et al., 2020 Nutrients; Ganuza et al., 2025 FrontNutr
    3. Ganuza et al., 2024 Front Nutr.
    4. Eslick et al., 2009 Int J Cardiol.